Approximately 10%-20% of diagnosed breast cancers are found to be triple-negative, meaning the breast cancer cells test negative for estrogen and progesterone receptors as well as HER2 receptors, genes that can play a role in the development of breast cancer. Triple-negative breast cancer can be more aggressive and difficult to treat as the cancer cells do not respond to hormonal therapies or therapies that target HER2 receptors.

A new study from the George Washington University (GW) Cancer Center found that nanoparticle-encapsulated doxorubicin is promising in the treatment of triple-negative breast cancer. Doxorubicin is a well-known anthracycline drug class used primarily in combination chemotherapy.

The majority of patients with triple-negative breast cancer receive doses of doxorubicin along with taxane and cyclophosphamide as preoperative chemotherapy. About 25%-45% of those patients respond to this medication and have excellent long-term prognosis.

“Nanomedicine is a very exciting avenue in modern drug development,” said Adam Friedman, MD, director of the Supportive Oncodermatology Clinic at GW Cancer Center, professor of dermatology at the GW School of Medicine and Health Sciences, and senior author of the study. “Nanotechnology offers many benefits, including the ability to purposefully customize your drug or diagnostic at the atomic scale, enhancing its ability to interact with its biological target and improve outcomes and potentially safety.”

In order to determine the most effective delivery of doxorubicin when encapsulated in a nanoparticle platform, Friedman and his collaborators at the Albert Einstein College of Medicine, synthesized several formulations of doxorubicin-containing nanoparticles to identify nanoparticle characteristics that best impact biologic activity against several resistant cancer cell lines.

With the nanoparticle, the team manipulated the size and timed release of the medication and found that increased cell kill in triple-negative breast cancer cells was associated with the smallest size of nanoparticles and the slowest release of doxorubicin.

“This study provides clues for new potential strategies utilizing and manipulating nanotechnology to overcome cancer cell drug resistance,” said Friedman. “We have our work cut out for us, but this study shows that we are moving in the right direction.”

The study is published in Precision Nanomedicine, a scientist-owned, not-for-profit, fully open-access journal that promotes all practical, rational, and progressive aspects of nanomedicine. It is supported by the European Foundation for Nanomedicine and by the International Society for Nanomedicine.

—Newswise